Boston University
Investigating the role of Oncostatin M in host defense against pneumonia
Abstract
dc:description.abstractPneumonia remains a leading cause of morbidity and mortality worldwide, especially among the elderly and children under the age of five. The increasing prevalence of antimicrobial-resistant pathogens has limited the effectiveness of conventional microbe-directed therapies, highlighting the urgent need for improved therapeutic approaches. Increasing evidence supports the notion that the host immune response is a critical determinant of pneumonia outcomes. Current host-directed therapies are promising but limited in their effectiveness. Thus, there is a need to improve our understanding of the host response to pneumonia so that we can develop better host-directed therapies. The interleukin-6 (IL-6) family cytokines are highly multifunctional regulators of immune and tissue responses and contribute to both homeostatic and pathological processes. While IL-6 has been most studied, the roles of other members, including Oncostatin M (OSM), are comparatively less well understood. The goal of my project is to understand the role of OSM during both viral and bacterial pneumonia using mouse models with genetic deletion of either the cytokine (OSM) or the receptor (OSMrβ). Our studies demonstrate that OSM is upregulated in the lungs both during Escherichia coli (E.coli) and influenza (X31 (influenza A strain/HKx31, H3N2) and PR8 (influenza A strain/Puerto Rico/8/34, H1N1)). Confirming previous reports, we observe that OSM is highly expressed by myeloid cells, including neutrophils, alveolar macrophages and classical monocytes. OSMrβ is mainly expressed by structural cells. We observe that whole-body OSM-knockout mice (OSM-/-) exhibit increased morbidity during pneumonia, with greater inflammation evidenced by an increase in recruitment of inflammatory leukocytes, decrease in tissue-resident alveolar macrophages and slower differentiation of Ly6C+ monocytes to alveolar macrophages. During E.coli pneumonia, we observe greater bacteremia and cell death with the loss of OSM. Conversely, OSMrβ is not required for OSM-mediated protection as whole-body OSMrβ-knockout mice (OSMrβ-/-) are protected from both influenza and E.coli pneumonia. Evaluation of pathways downstream of OSM treatment of OSMrβ-/- lungs demonstrates rmOSM-induced Signal Transducer and Activator of Transcription 3 (STAT3) activation in endothelial cells but a loss of activation in epithelial cells, suggesting endothelial cells respond to OSM in an OSMrβ-independent manner. Since these cells express high levels of Leukemia Inhibitory Factor receptor (LIFrβ), we propose that OSM-LIFrβ signaling is sufficient to mediate the protective effects of OSM during pneumonia. In summary, our studies demonstrate that OSM is an important mediator of tissue defense against viral and bacterial pneumonia and reveal that OSMrβ-independent signaling is sufficient for this protective effect.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Microbiology
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Lee, Yewoo
- Advisor dc:contributor.advisor
-
- Traber, Katrina E.
- ORCID dc:identifier.orcid
Subjects
dc:subject × 9Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53551